Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates

Company Performance - Charles River Laboratories (CRL) reported quarterly earnings of $3.12 per share, exceeding the Zacks Consensus Estimate of $2.50 per share, and up from $2.80 per share a year ago, representing an earnings surprise of +24.80% [1][2] - The company posted revenues of $1.03 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.01%, with year-ago revenues also at $1.03 billion [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $2.37 on revenues of $958.76 million, and for the current fiscal year, it is $9.62 on revenues of $3.89 billion [8] - The estimate revisions trend for Charles River was favorable ahead of the earnings release, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [7] Industry Context - The Medical Services industry, to which Charles River belongs, is currently in the top 30% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [9] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [6]